Lifecore Biomedical (LFCR) – Research Analysts’ Recent Ratings Changes

A number of research firms have changed their ratings and price targets for Lifecore Biomedical (NASDAQ: LFCR):

• 10/2/2026 – Lifecore Biomedical was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
• 9/29/2026 – Lifecore Biomedical was downgraded by Barrington Research from “outperform” to “hold”.
• 9/28/2026 – Lifecore Biomedical was downgraded by Craig Hallum from “strong-buy” to “hold”.
• 9/28/2026 – Lifecore Biomedical was downgraded by William Blair from “outperform” to “hold”.
• 9/9/2026 – Lifecore Biomedical was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
• 8/25/2026 – Lifecore Biomedical was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.

Lifecore Biomedical, Inc is a contract development and manufacturing organization that provides specialized services to pharmaceutical, biotechnology and medical device companies. The company develops and manufactures complex injectable products, supporting customers from formulation and process development through aseptic filling, packaging and commercial production.

Lifecore has particular expertise in fermentation-based products and hyaluronic acid, a biopolymer used in ophthalmic, orthopedic, aesthetic and other medical applications.